Hematopoietic cell transplantation (HCT) is currently the only treatment with curative potential for myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD)
. Among patients with less advanced MDS, 3-year survival rates of 65% to 75% are achieved with HLAidentical related and unrelated donors. The probability of relapse is less than 5%. Among patients with advanced MDS (≥5% marrow blasts), about 35% to 45% who receive transplants from related donors and 25% to 30% who receive transplants from unrelated donors are in remission beyond 3 years. The incidence of posttransplantation relapse is 10% to 35%. Criteria of the International Prognostic Scoring System (originally developed for nontransplant patients) also predict relapse and survival after HCT. Transplantation is successful in 50% to 80% of patients with MPD if performed before leukemic transformation. Depending on the individual risk profile, a considerable number of patients with MDS or MPD are cured by allogeneic HCT. However, HCT should be performed before disease progression. Outcome of patients with treatment-related MDS or with relapse after transplantation remains poor. At present, no definite conclusions can be made with regard to reduced-intensity transplantation regimens.
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MYELODYSPLASTIC SYNDROMES
Myelodysplastic syndromes (MDS) are clonal stem cell disorders that are characterized by ineffective hematopoiesis and a propensity to evolve into acute myelogenous leukemia (AML) (secondary AML). 1, 2 The median age at diagnosis is about 70 years, and approximately 50% of patients with primary MDS have clonal cytogenetic abnormalities. 1, 2 Depending on the hematopoietic lineages involved, patients present with anemia, leukopenia, and thrombocytopenia.
According to the French-American-British (FAB) classification, MDS include refractory anemia (RA [<5% marrow blasts]), RA with ringed sideroblasts (RARS [>15% marrow ringed sideroblasts]), RA with excess blasts (RAEB [5%-20% marrow blasts]), RAEB in transformation (RAEB-T [21%-30% marrow blasts]), and chronic myelomonocytic leukemia (CMML). 3 The World Health Organization recently proposed a revised classification including RA, RARS, refractory cytopenia with multilineage dysplasia, 5q-syndrome, RAEB I (5%-10% marrow blasts), RAEB II (11%-20% marrow blasts), and unclassifiable MDS; RAEB-T is to be grouped with AML. 4 In addition, CMML with high white blood cell counts is now considered a myeloproliferative disorder (MPD).
For editorial comment, see page 941.
The incorporation of cytogenetic findings and the number of cytopenias, in addition to the blast count, into a new risk scoring system termed the International Prognostic Scoring System (IPSS) provides improved prognostic precision. 5 According to the IPSS, patients are stratified into 4 risk groups (low, intermediate-1, intermediate-2, and high) on the basis of numerical scores for marrow blast percentage, number of cytopenias, and cytogenetic abnormalities (Table 1) . Median survival for patients in these 4 groups has been estimated at 5.7 (low), 3.5 (intermediate-1), 1.2 (intermediate-2), and 0.4 (high) years, respectively. 5 Although originally designed for nontransplant patients, recent reports have shown that the IPSS allows prediction of survival and relapse probabilities after hematopoietic cell transplantation (HCT). 6, 7 
MYELOPROLIFERATIVE DISORDERS
Myelofibrosis of various degrees can be associated with MDS. However, fibrosis, as a reactive process of nonclonal fibroblasts, more typically characterizes MPDs. Myeloproliferative disorders include chronic myeloid leukemia (a well-defined entity, which will not be discussed in this article), CMML, agnogenic myeloid metaplasia (AMM), polycythemia vera (PV), and essential thrombocythemia (ET). When Dameshek 8 originally classified MPDs, he stated that "if we examine these various syndromes…we find it difficult to draw any clear-cut dividing lines; in fact, so many transition forms exist…." However, transitional forms exist not only among MPD entities but also between MDS and MPDs. Although in AMM, fibrosis develops de novo, myelofibrosis (with myeloid metaplasia) usually represents an end stage of PV and ET.
Myeloproliferative disorders are characterized by expansion of a hematopoietic stem cell clone resulting in excessive production of cells in 1 or more hematopoietic lineages. With varying frequency, an MPD may evolve into blast crisis comparable to AML, more so with AMM and PV than with ET. Similar to MDS, MPDs are predominantly diseases of older patients. The median age at diagnosis is 55 to 65 years. [9] [10] [11] As with MDS, the clinical presentation depends on the number of marrow lineages involved. Whereas PV is characterized by erythrocytosis, with or without leukocytosis and thrombocytosis, highly elevated platelet counts are the hallmark of ET. However, in later stages of PV and ET, excessive myelofibrosis and cytopenias may be prominent. Splenomegaly is a common feature of all MPDs. The classic features of AMM are marrow fibrosis, leukoerythroblastic peripheral blood smear, and extramedullary hematopoiesis. Most patients with AMM have anemia, and white blood cell and platelet counts can be either elevated or reduced. Several prognostic scoring systems have been proposed; the most widely accepted is the Lille Scoring System, which assigns patients to 1 of 3 risk groups based on hemoglobin levels and white blood cell count (Table 2) . 10, 11 Recently, the group at the M. D. Anderson Cancer Center, Houston, Tex, analyzed data from patients with CMML and generated a prognostic score for this particular disease group based on hemoglobin levels, marrow blast percentage, lymphocyte count, and presence of peripheral blood immature myeloid cells. 12 
LITERATURE SEARCH
We performed a computerized search of the National Library of Medicine electronic database (MEDLINE/PubMed) in October 2002 for this report. Validity of studies was assessed according to published guidelines. 13 Search terms included adults, myelodysplastic syndrome(s), myelodysplasia, myeloproliferative disorders, myelofibrosis, agnogenic myeloid metaplasia, essential thrombocythemia, polycythemia vera, allogeneic, autologous, transplantation, and reduced intensity in various combinations. Articles published since 1990 are included in the reference list of this report. More recent reports and larger studies are discussed in greater detail. The list was cross-checked with reference lists contained in the articles. In the absence of prospective randomized trials comparing HCT with other treatment approaches or comparing different transplantation regimens, well-designed prospective phase 1 and 2 studies and retrospective data surveys including more than 10 patients with MDS were considered. For MPDs, studies with fewer than 10 patients were also included but not single case reports. Review articles were considered if they contained original study data. Special emphasis was placed on the availability of data on relapse-free survival, relapse incidence, and nonrelapse mortality.
GENERAL CONSIDERATIONS FOR HCT IN MDS AND MPD
Hematopoietic cell transplantation is an established procedure for various malignant and nonmalignant disorders. 14 Although indications are relatively clear for some diseases, they are less well defined for MDS and MPDs. In many patients with MDS or MPDs, the disease is managed conservatively for extended periods. In general, however, these therapeutic approaches are palliative. Because both MDS and MPDs are hematopoietic stem cell disorders, they are amenable to HCT, currently the only therapeutic approach with curative potential. Because the clinical course of MDS (and MPDs) is highly variable, an accurate assessment of the prognosis is essential before deciding on therapy, in particular HCT. At present, the IPSS provides the most useful system for patients with MDS and the Lille score for patients with MPDs.
To facilitate the decision process about whether to proceed to HCT, an algorithm for MDS treatment was developed by the National Comprehensive Cancer Network Myelodysplasia Panel. Patients in low or intermediate-1 IPSS risk group may do well for a while with supportive care or low-intensity therapy, particularly if their clinical course is stable or their performance status or age (>60-65 years) precludes them from undergoing HCT. Hematopoietic cell transplantation may be offered to patients up to 60 or 65 years of age with good performance status in the intermediate-1 risk group if suitable donors are available. The indication for transplantation should be reassessed in any patient in whom the clinical course suggests disease progression.
For patients younger than 60 to 65 years with good performance status in intermediate-2 or high-risk IPSS groups, HCT appears to be the treatment of choice. In patients older than 60 to 65 years with adequate performance status, low-intensity therapy may be preferable unless they qualify for a nonmyeloablative transplantation (see subsequent discussion).
The optimal timing of HCT for patients with MDS is an area of ongoing investigation. Preliminary data suggest that patients in the low/intermediate-1 IPSS risk group have the highest life expectancy with initial conservative management, followed by HCT after 2 to 4 years (and before leukemic transformation). 15 According to these data, patients with advanced MDS (intermediate-2 and high-risk groups) may gain a 5-to 25-month survival advantage with immediate HCT compared with HCT at the time of progression to AML. 15 The role of intensive chemotherapy for MDS before HCT is a matter of debate. de Witte et al 16 described 184 patients who received 1 or 2 remission-induction courses followed by consolidation if a complete remission was achieved. Patients then underwent either allogeneic or autologous HCT depending on donor availability. Four-year overall survival in the entire cohort was 26%, and relapse-free survival was 29%. Controlled studies comparing HCT with and without prior chemotherapy are necessary to address the issue of whether pretransplantation chemotherapy positively impacts overall survival, relapse-free survival, and relapse incidence.
TRANSPLANTATION APPROACHES Myeloablative HCT for MDS
Thirty-one articles on myeloablative allogeneic HCT in patients with MDS published between 1990 and October 2002 were retrieved from PubMed. 6, 7, These studies had between 12 and 1378 patients with median ages ranging from 19.0 to 58.8 years. The conditioning regimens differed widely depending on the active protocols at the time of transplantation at the respective centers (the regimen used for most patients at the respective centers is listed): cyclophosphamide-total body irradiation (TBI), 6, 9, 22 busulfan-TBI, 44 cyclophosphamide-TBI with liver and lung shielding, 38 busulfan-cyclophosphamide, 20, 23, 25, 30, 35, 36, 42 busulfan-cyclophosphamide-cytosine arabinoside, 21 cyclophosphamide-TBI-busulfan, 24 cyclophosphamide-TBIcytosine arabinoside, 18 cyclophosphamide-TBI-cytosine arabinoside or etoposide, 27 busulfan-cyclophosphamidethiotepa, 39 TBI-cytosine arabinoside, 33 cyclophosphamide-TBI-idarubicin, 29 TBI-based regimens, 7, 17, 31, 32 or various regimens. 26, 28, 34, 41, 43 In these studies, depending on the individual risk profile, relapse-free survival at 2 to 7 years ranged from 8% to 74%. Relapse incidence and nonrelapse mortality were between 0% and 71% and 28% and 72%, respectively. Data on relapse-free survival were available in all studies but not on relapse incidence and nonrelapse mortality. Various prognostic parameters to predict relapse, survival, and nonrelapse mortality were analyzed by different statistical models; percentage of marrow blasts (disease stage/FAB subgroup) at the time of transplantation was consistently shown to be predictive of relapse. 7, 17, 19, 22, 24, [26] [27] [28] [30] [31] [32] 35, 37, [40] [41] [42] 44 Cytogenetic IPSS category 6, 30, 35, 42, 44 and the total IPSS score 6, 7, 35, 42 were also strong predictors of relapse ( Figure 1) . Younger age 19, 20, 22, 25, 28, 31, 32, 36, 37 and shorter disease duration 22, 25, 31, 32, 41, 44 correlated with improved overall survival and relapse-free survival primarily because of a lower nonrelapse mortality.
Less Advanced MDS.-The best results with allogeneic HCT are achieved in patients with low myeloblast counts (defined as RA/RARS) at transplantation and in those without high-risk cytogenetic abnormalities, as defined by the IPSS. Among 131 patients with MDS reported to the European Group for Blood and Marrow Transplantation (EBMT) who received transplants from HLA-identical siblings, 5-year relapse-free survival was 52%, and relapse incidence was 13% for patients with RA/RARS. 31 With HLA-matched unrelated transplants (reported by the same group) at 2 years, relapse-free survival was 24%, and relapse incidence was 13%. 32 In a cohort of 510 patients with MDS who received transplants from unrelated donors under the auspices of the National Marrow Donor Program, those who underwent a conditioning regimen with busulfan-cyclophosphamide fared better than those who underwent other regimens. 41 Relapse-free survival and relapse rate in patients with RA were 40% and 5%, respectively. 41 Investigators at the Fred Hutchinson Cancer Research Center (FHCRC) recently reported results achieved with a regimen of busulfan-cyclophosphamide in which the busulfan dose was adjusted to maintain steady-state plasma levels of 800 to 900 ng/mL (targeted busulfan). 42 Among 69 patients with RA/RARS, the 3-year probability of relapse-free survival was 68% among those who received a transplant from HLA-identical siblings and 70% for those who received a transplant from unrelated donors. 42 Among all patients, the incidence of nonrelapse mortality was 31% at 3 years, and relapse occurred in 5% of patients with RA/ RARS. Evidence showed that outcome was superior in patients who underwent transplantation with granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPC) rather than marrow. A retrospective survey of the EBMT comparing marrow and granulocyte colony-stimulating factor-mobilized PBPC for allogeneic HCT from HLA-identical siblings (with either TBI-or chemotherapy-based conditioning regimens) confirmed that the incidence of treatment failure in all MDS sub- Relapse-free survival (%) Figure 1 . Impact of International Prognostic Scoring System (IPSS) on outcome of patients with myelodysplastic syndromes. The "+" indicates censored patient; in 7 patients, an IPSS score could not be assigned. Top, Relapse-free survival. Bottom, Cumulative incidence of relapse. Reprinted with permission from Deeg et al. 42 groups was lower when PBPC were used as a stem cell source. 43 Also, nonrelapse mortality was reduced with PBPC, except among patients with RA and high-risk cytogenetics in whom no difference was observed.
Although the median age of study patients increased from the early 1990s to the present, investigators have been reluctant to consider HCT for MDS in patients older than 55 or 60 years. One study reported results in 50 patients with MDS, 55 to 66 years of age, who received either a combined regimen of busulfan-cyclophosphamide with fractionated TBI or busulfan-cyclophosphamide alone. 35 Donors were HLA-identical siblings in 34, HLA-nonidentical family members in 4, identical twins in 4, and unrelated volunteers in 6 patients. At 3 years, relapse-free survival was 53% for patients with RA; when only transplants from HLA-identical siblings were considered, relapse-free survival was 67%. Survival in all FAB categories was highest among patients who were conditioned with targeted busulfan-cyclophosphamide. Thus, these studies show a success rate of almost 70% in patients with early MDS and suggest that the lack of a suitably matched related donor should not be a reason to forsake plans for transplantation. However, despite encouraging results in many of these series, nonrelapse mortality due to infections, graft-vs-host disease, and single and multiorgan toxicity was high. 6, 7, Advanced MDS.-The risk of posttransplantation relapse increases with the proportion of marrow blasts present at the time of transplantation (advanced MDS [RAEB/RAEB-T]). 17, 19, 22, 26, 28, [30] [31] [32] 42 Relapse rates in the range of 14% to 71% have been reported in patients with RAEB, RAEB-T, or secondary AML. 19, 22, 24, 26, [30] [31] [32] 35, 42 More intensive conditioning regimens including busulfan-cyclophosphamide-TBI, 24 cyclophosphamide-TBI-cytosine arabinoside or etoposide, 27 cyclophosphamide-TBI-idarubicin, 29 or busulfan-cyclophosphamide-thiotepa 39 showed high nonrelapse mortality (68%, 24 50%, 27 42%
39
) with similar relapse-free survival and relapse rates compared with busulfan-cyclophosphamide or cyclophosphamide-TBI regimens. Thus, regimen intensification does not appear to be beneficial. The EBMT reported 5-year relapse-free survival of 34%, 19%, and 26% for patients with RAEB, RAEB-T, and secondary AML, respectively, after receiving transplants from HLA-identical siblings. 31 The relapse rate was 44% for RAEB, 52% for RAEB-T, and 50% for secondary AML. Nonrelapse mortality was highest in patients with RAEB-T (60%), followed by those with secondary AML (48%) and RAEB (38%). In patients receiving HLA-matched unrelated donor transplants, relapse-free survival was 27% for RAEB, 8% for RAEB-T, and 27% for secondary AML. 32 A recent report from the International Bone Marrow Transplant Registry on 452 patients who received transplants from HLA-identical siblings (44% underwent conditioning with TBI-containing regimens) between 1989 and 1997 found a relapse-free survival of 33% at 3 years for patients 18 years or older with RAEB/RAEB-T; for the entire group, relapse incidence and nonrelapse mortality were 23% and 37%, respectively. 7 In a trial of 60 patients with RAEB, RAEB-T, CMML, or secondary AML (20 patients received transplants from related donors and 40 from unrelated donors) who were conditioned with busulfan-TBI without the use of cyclophosphamide, the Kaplan-Meier estimate of survival at 3 years was 26% with a relapse incidence of 25%. 44 The relapse rate was comparable to that observed previously with a regimen combining busulfan-TBI with cyclophosphamide. However, despite the omission of cyclophosphamide, nonrelapse mortality was considerable (38% at 100 days), particularly for patients who received transplants from unrelated donors. These data suggest that TBI may not be the best modality to prepare patients with MDS for transplantation. In conceptual agreement with this notion, the National Marrow Donor Program analysis cited previously showed that patients in all FAB categories who were conditioned with non-TBI regimens had a higher probability of overall survival and relapse-free survival than those conditioned with TBI. 41 As observed for less advanced MDS, the use of PBPC tended to be associated with a lower treatment failure incidence than the use of marrow in all subgroups with advanced MDS. 43 The aforementioned FHCRC trial used the regimen of targeted busulfan-cyclophosphamide not only for less advanced but also for advanced MDS. Among patients with RAEB, relapse-free survival at 3 years was 45% for those who received transplants from HLA-identical siblings and 40% for those who received transplants from unrelated donors. 42 The corresponding rates for RAEB-T/secondary AML were 33% and 17%, respectively. In patients 55 to 66 years of age, the Kaplan-Meier estimates of relapse-free survival at 3 years were 46% for RAEB and 33% for RAEB-T/secondary AML. 35 These data show that despite higher relapse rates a considerable number of patients can be cured by allogeneic HCT, even those with advanced stages of MDS.
Myeloablative HCT for MPDs
AMM/Myelofibrosis and PV/ET.-Although numerous case reports have been published, studies of allogeneic HCT for patients with MPDs other than chronic myeloid leukemia are rare. [45] [46] [47] [48] [49] [50] [51] Singhal et al 45 treated 3 patients with HLA-identical sibling transplants after conditioning with TBI-melphalan. Of these 3 patients, 1 was alive at the time of reporting. Anderson et al 47 described 13 patients (median age, 40 years), 9 of whom received HLA-identical sibling transplants. Three underwent conditioning with TBI-based regimens and 10 with busulfan-cyclophosphamide. The 2-year survival was 77%. 47 At the M. D. Anderson Cancer Center, 6 patients received transplants from HLA-identical sibling donors with use of 3 different conditioning regimens. 48 Three patients were alive for more than 24, 28, and 32 months after transplantation. Guardiola et al 49 retrospectively analyzed results in 55 patients reported from multiple institutions. Most patients had AMM (8 patients had myelofibrosis after ET) and received transplants from HLA-identical siblings. Thirty-five patients underwent conditioning with TBI-containing regimens and the remaining with busulfan-cyclophosphamide. The 5-year overall survival was 47%, and the nonrelapse mortality at 1 year was 27%. Low hemoglobin values and the presence of osteomyelosclerosis identified high-risk patients (Figure 2) . 49 A recent report from this center presented updated results for 25 patients with PV or ET who received either marrow (n=19) or PBPC (n=6) from related (n=16) or unrelated (n=9) donors. 51 Patients underwent transplantation because of either myelofibrosis with splenomegaly and peripheral blood cytopenias or the development of MDS-AML. Various conditioning regimens were used. At a median follow-up of 41 months, survival was 64% for all patients and 82% for those conditioned with targeted busulfan-cyclophosphamide. Multifactorial analysis identified conditioning regimens other than targeted busulfan-cyclophosphamide and increasing disease severity (based on the Lille classification) as significant negative risk factors for relapse-free survival. Patients who underwent transplantation before they showed an excess of blasts fared better than those with more than 5% blasts. These data provide strong evidence that HCT offers curative therapy for patients with advanced AMM and ET or PV.
Chronic Myelomonocytic Leukemia.-Because CMML is a rare disorder and is considered under MDS in the FAB classification, treatment results are primarily reported together with other MDS entities. 20, 22, 24, 26, 27, 29, 31, 32, 35, 36, [39] [40] [41] [42] 44 To our knowledge, only 2 studies have reported separately on patients with CMML after allogeneic transplantation. 52, 53 At this center, 21 patients with CMML received transplants from related (n=15) or unrelated (n=6) donors with use of different conditioning regimens. Three-year relapse-free survival and relapse incidence were 39% and 25%, respectively. 52 Although only 1 patient with normal blast counts had a relapse, 4 relapses occurred among 12 patients with excess blasts. Shorter disease duration was associated with improved outcome. The largest series reported to date describes results in 50 patients who underwent transplantation after conditioning with TBI-based (n=26) or chemotherapy-based (n=24) regimens. 53 Patients received marrow (n=40), PBPC (n=9), or both (n=1) from HLAidentical siblings (n=38) or other donors (n=12). Relapsefree survival, nonrelapse mortality, and relapse incidence at 2 years were 18%, 55%, and 42%, respectively. 53 Earlier transplantation, use of male donors, use of unmanipulated transplants, and development of acute graft-vs-host disease favored a better outcome, although differences were not statistically significant. The probability of relapse tended to be lower in patients with acute graft-vs-host disease grades 2 through 4 (24% vs 54%; P=.07), suggesting the presence of a graft-vs-CMML effect. Outcomes tended to be inferior in patients with excess blasts and those who had received pretransplantation cytotoxic therapy. 52, 53 AUTOLOGOUS HCT FOR MDS/MPD Compared with allogeneic transplantation, autologous HCT is associated with lower nonrelapse mortality and holds promise in situations in which a "pure" population of normal hematopoietic stem cells is obtainable. The EBMT reported results in 79 patients with MDS/AML (19 patients had MDS) and showed a 2-year relapse-free survival of 28% and a relapse incidence of 69% after autologous HCT. 54 Nonrelapse mortality was less than 10%. Only patients who achieved complete remission after induction chemotherapy were included. Wattel et al 55 prospectively assessed feasibility of autologous HCT (either with bone marrow or PBPC) after a conditioning regimen of busulfan-cyclophosphamide in 24 of 39 patients who achieved complete remission after induction chemotherapy; 50% were alive 8 to 55 months after transplantation. de Witte et al 16 presented data on 184 patients with MDS/secondary AML who received allogeneic or autologous transplants (depending on donor availability) after induction chemo- therapy; 54% achieved complete remissions. With or without additional consolidation, 72% of patients with a donor available received allogeneic transplants, and 61% of patients received autologous transplants. The 4-year relapsefree survival rates in the groups with and without allogeneic donors were 31% and 27%, respectively. 6 These data suggest that autologous HCT can result in long-lasting remission in some patients and should be considered a therapeutic option if there is no possibility of allogeneic HCT.
The role of autologous HCT with PBPC has also been investigated in older patients with end-stage myeloid metaplasia and myelofibrosis 56 ; 21 patients underwent a conditioning regimen of busulfan infused with previously harvested autologous peripheral blood cells. The median time to both neutrophil and platelet engraftment was 21 days; 5 patients received infusions of "backup" stem cells. Erythroid responses occurred in 10 of 17 patients with anemia, and platelet counts increased in 4 of 8 patients with fewer than 100,000 platelets. Regression of marrow fibrosis was observed in several patients and a decrease in spleen size in 7 of 10 evaluable patients. Thus, a substantial proportion of patients derived a clinical benefit. The 2-year overall survival was 61%.
NONMYELOABLATIVE HCT FOR MDS AND MPD
The recent development and application of reduced-intensity conditioning or nonmyeloablative transplantation regimens ("minitransplantations") have stirred considerable interest. 57 The rationale of this approach is that a reduction in the intensity of the conditioning regimen will reduce early transplantation-related toxicity. Administration of immunosuppressive drugs after transplantation facilitates donor cell engraftment and enhances the effect of donor lymphocytes against patients' cells. In view of the generally high incidence of nonrelapse mortality in older patients, such an approach is particularly attractive for the treatment of such patients with MDS. Reduced-intensity conditioning regimens might also be of interest in patients with relapse after conventional transplantation, particularly if debulking with chemotherapy before such a transplantation is successful. The field is developing rapidly, and some limited results with reduced-intensity conditioning transplantation regimens for patients with MDS have been presented. [58] [59] [60] [61] [62] Kröger et al 58 reported a relapse-free survival of 12% at 2 years among 12 patients with high-risk MDS after nonmyeloablative HCT from related (n=5) or unrelated (n=7) HLA-matched donors. A report from Spain of 37 patients with AML/MDS who underwent transplantation showed a 1-year nonrelapse mortality of 5% and a relapse-free survival of 66% for the entire cohort. 59 In a recent British trial, 23 patients with MDS were conditioned with fludarabinebusulfan-CAMPATH-1H and received bone marrow or PBPC from HLA-identical siblings (n=7) or unrelated alternative donors (n=16). The 2-year relapse-free survival was 39%, and the relapse incidence was 31%. 60 In a small pilot study, 4 patients with myelofibrosis and myeloid metaplasia underwent a nonmyeloablative conditioning regimen, including fludarabine and melphalan. 63 All patients received PBPC from HLA-identical siblings and are alive at a median follow-up of 13 months. Thus, reduced-intensity conditioning regimens are of interest for preparing patients with MDS and MPDs for transplantation. However, failure of engraftment and disease progression have been problems in some studies. Additional work is required, particularly with the use of unrelated donors.
SECONDARY MDS
Secondary (treatment-related) MDS occurs after therapy for various disorders. Incidence rates of 0.58% to 7.4% for secondary MDS/acute leukemia have been reported in patients after autologous HCT for Hodgkin disease, nonHodgkin lymphoma, and breast carcinoma. [64] [65] [66] [67] The median time from primary disease to secondary MDS ranges from fewer than 4 years to 9 years or more. Abnormal, usually high-risk karyotypes (monosomy 7; complex abnormalities) are present in 80% to 90% of patients with secondary MDS. [64] [65] [66] Exposure to irradiation and chemotherapy, given for the patient's original disease, is thought to be causative. Because prior therapy is expected to result in tissue damage, the sequelae are also likely to predispose the patient who undergoes transplantation for secondary MDS to substantial morbidity and mortality. Only a few studies have been reported. [66] [67] [68] [69] [70] Among 552 patients who underwent autologous HCT for non-Hodgkin lymphoma, Friedberg et al 66 observed 41 who developed MDS, for an actuarial incidence of 19.8% at 10 years. Thirteen patients underwent allogeneic HCT, all of whom died; median survival was only 1.8 months. A French group described 70 patients who underwent allogeneic HCT (various conditioning regimens were used) for therapy-related MDS and AML. 68 Overall, 54 patients died: 19 of relapse, 34 of nonrelapse mortality, and 1 of relapse of the primary disease. Age older than 37 years, absence of complete remission at HCT, and intensive schedules for conditioning were associated with poor outcome. Relapsefree survival, relapse incidence, and nonrelapse mortality at 2 years were 28%, 42%, and 49%, respectively. 68 Of note, 33 patients had received pretransplantation induction chemotherapy, and patients who achieved a remission had a substantially higher chance of relapse-free survival than did those who were not in remission.
We evaluated outcome among 111 consecutive patients with secondary MDS who received transplants at the FHCRC between 1971 and 1998 from either related or unrelated donors, using the same conditioning regimens as employed concurrently for patients with de novo MDS. 69 The 5-year relapse-free survival was 8% for patients conditioned with TBI, 19% for those given busulfan-cyclophosphamide, and 30% for patients conditioned with targeted busulfan-cyclophosphamide. The 5-year relapse incidence was 40% for secondary AML, 40% for RAEB-T, 26% for RAEB, and 0% for RA and RARS. 69 Thus, as with de novo MDS, disease stage was the most important risk factor for outcome, and the conditioning regimen had a major impact. Ballen et al 70 reported a relapse-free survival of 24% and nonrelapse mortality of 50% at 3 years for 18 patients with secondary MDS treated with HCT from matched related or unrelated donors after use of various conditioning regimens.
Thus, results obtained with allogeneic HCT for treatment-related MDS are currently unsatisfactory, although transplantation may be the only viable option for many of these patients. Efforts must be directed first at the prevention of secondary MDS and second at improved tolerability of transplantation conditioning regimens.
POSTTRANSPLANTATION RELAPSE
Outcome after posttransplantation relapse remains poor. Conceivably, reduced-intensity conditioning and second transplants might be an option, particularly if carried out before an increase in myeloblasts. 71, 72 Reports on the efficacy of donor lymphocyte infusions in patients with MDS after relapse of allogeneic HCT are rare and include between 1 and 11 patients. [73] [74] [75] [76] [77] A Japanese series noted complete remission in 5 of 11 patients with MDS. 75 Among 57 patients, including 7 with MDS, Levine et al 76 achieved a 1-year relapse-free survival of 34% in patients who responded to donor lymphocyte infusion vs 0% among those who did not. A study by Collins et al 77 included 5 patients with MDS, 2 of whom responded to donor lymphocyte infusion. We have given donor lymphocyte infusion to 7 patients with MDS (5 with RAEB and 2 with RA), and 3 (all with RAEB) achieved complete remission. Two patients are alive and disease free at more than 2 years. These observations are of interest, but firm conclusions cannot be made at this point.
CONCLUSION AND FUTURE DIRECTIONS
Patients with high-risk MDS who have suitable HLAmatched related or unrelated donors should undergo transplantion early in the course of disease. Patients with less advanced MDS based on FAB criteria (<5% marrow blasts) but with high-risk IPSS cytogenetic findings or severe multilineage cytopenias according to IPSS and transfusion dependence also should be considered for early transplantation. Patients with MDS with low-risk IPSS cytogenetic features and without severe cytopenias may do well for extended periods with more conservative management. 78 Hematopoietic cell transplantation can be performed successfully, even in the seventh decade of life. Available data suggest that non-TBI regimens, in particular with targeted busulfan-cyclophosphamide conditioning, are better tolerated than TBI-containing regimens and that the use of PBPC offers an advantage over bone marrow cells. Allogeneic HCT is a therapeutic option with curative potential for patients with MPDs. Transplantation should be performed before myelosclerosis has developed or acute leukemia has evolved. The role of reduced-intensity conditioning/nonmyeloablative transplants, other than for patients older than 60 to 65 years, remains to be determined. Future investigations will focus on identifying additional prognostic parameters, allowing prediction of prognosis, evaluation of new conditioning regimens, and determination of the optimal timing of HCT. 15, [79] [80] [81] 
